Expression of a candidate cadherin in T lymphocytes.

Por Cepek, K L, Rimm, D L, Brenner, M B
Publicado em 1996

Quantitative assessment of miR34a as an independent prognostic marker in breast cancer

Por Agarwal, Seema, Hanna, J, Sherman, M E, Figueroa, J, Rimm, D L
Publicado no Br J Cancer (2015)

Alpha 1(E)-catenin is an actin-binding and -bundling protein mediating the attachment of F-actin to the membrane adhesion complex.

Por Rimm, D L, Koslov, E R, Kebriaei, P, Cianci, C D, Morrow, J S
Publicado em 1995

The expression of p120ctn protein in breast cancer is independent of alpha- and beta-catenin and E-cadherin.

Por Dillon, D. A., D'Aquila, T., Reynolds, A. B., Fearon, E. R., Rimm, D. L.
Publicado em 1998

Growth factor receptor-bound protein-7 (Grb7) as a prognostic marker and therapeutic target in breast cancer

Por Nadler, Y., González, A. M., Camp, R. L., Rimm, D. L., Kluger, H. M., Kluger, Y.
Publicado em 2010

Association of constitutively activated hepatocyte growth factor receptor (Met) with resistance to a dual EGFR/Her2 inhibitor in non-small-cell lung cancer cells

Por Agarwal, S, Zerillo, C, Kolmakova, J, Christensen, J G, Harris, L N, Rimm, D L, DiGiovanna, M P, Stern, D F
Publicado em 2009

Identification of proteomic biomarkers predicting prostate cancer aggressiveness and lethality despite biopsy-sampling error

Por Shipitsin, M, Small, C, Choudhury, S, Giladi, E, Friedlander, S, Nardone, J, Hussain, S, Hurley, A D, Ernst, C, Huang, Y E, Chang, H, Nifong, T P, Rimm, D L, Dunyak, J, Loda, M, Berman, D M, Blume-Jensen, P
Publicado no Br J Cancer (2014)

EGFR expression is associated with decreased benefit from trastuzumab in the NCCTG N9831 (Alliance) trial

Por Cheng, H, Ballman, K, Vassilakopoulou, M, Dueck, A C, Reinholz, M M, Tenner, K, Gralow, J, Hudis, C, Davidson, N E, Fountzilas, G, McCullough, A E, Chen, B, Psyrri, A, Rimm, D L, Perez, E A
Publicado no Br J Cancer (2014)

Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial

Por Shi, W., Jiang, T., Nuciforo, P., Hatzis, C., Holmes, E., Harbeck, N., Sotiriou, C., Peña, L., Loi, S., Rosa, D. D., Chia, S., Wardley, A., Ueno, T., Rossari, J., Eidtmann, H., Armour, A., Piccart-Gebhart, M., Rimm, D. L., Baselga, J., Pusztai, L.
Publicado no Ann Oncol (2017)

Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial

Por Shi, W, Jiang, T, Nuciforo, P, Hatzis, C, Holmes, E, Harbeck, N, Sotiriou, C, Peña, L, Loi, S, Rosa, D D, Chia, S, Wardley, A, Ueno, T, Rossari, J, Eidtmann, H, Armour, A, Piccart-Gebhart, M, Rimm, D L, Baselga, J, Pusztai, L
Publicado no Ann Oncol (2018)

A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers

Por Gettinger, S. N., Choi, J., Mani, N., Sanmamed, M. F., Datar, I., Sowell, Ryan, Du, Victor Y., Kaftan, E., Goldberg, S., Dong, W., Zelterman, D., Politi, K., Kavathas, P., Kaech, S., Yu, X., Zhao, H., Schlessinger, J., Lifton, R., Rimm, D. L., Chen, L., Herbst, R. S., Schalper, K. A.
Publicado no Nat Commun (2018)

The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014

Por Salgado, R., Denkert, C., Demaria, S., Sirtaine, N., Klauschen, F., Pruneri, G., Wienert, S., Van den Eynden, G., Baehner, F. L., Penault-Llorca, F., Perez, E. A., Thompson, E. A., Symmans, W. F., Richardson, A. L., Brock, J., Criscitiello, C., Bailey, H., Ignatiadis, M., Floris, G., Sparano, J., Kos, Z., Nielsen, T., Rimm, D. L., Allison, K. H., Reis-Filho, J. S., Loibl, S., Sotiriou, C., Viale, G., Badve, S., Adams, S., Willard-Gallo, K., Loi, S.
Publicado no Ann Oncol (2015)